Comparing the current results to its competitors, Opus Genetics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -50.64 %, despite the revenue increase by the most of its competitors of 50.84 %, recorded in the same quarter.
Opus Genetics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 219.86 %
Opus Genetics Inc 's Comment on Competition and Industry Peers
The company and its development partners face competition from both branded and generic pharmaceutical firms, as well as products in development. Competitors generally have greater financial and human resources and more experience in drug development, research and development, and commercialization. They also compete in recruiting personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary products or technologies. Smaller and early-stage companies may become significant competitors if they form partnerships with large, established firms.
In the area of inherited retinal diseases (IRDs), there are currently no direct competitors for the company's OPGx-LCA5 or OPGx-BEST1 gene therapy programs. However, various companies are developing gene therapies for IRDs that may compete in the future. No active IRD gene therapy programs exist for the LCA5, BEST1, NMNAT1, or MERTK genes. For the RDH12 gene, an investigator-initiated trial is underway in China, and MeiraGTX has a program in development. Octant Bio has a preclinical program in IND-enabling studies targeting the RHO gene. Additionally, cell therapies and optogenetics may present competition in later development stages.
In the presbyopia treatment market, multiple potential competitors include Lenz Therapeutics with LNZ100 (1.75% Aceclidine) and AbbVie with VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25%.
March 5, 2025
The field of ocular gene therapies has seen significant advancements in recent years, particularly for retinopathies such as Leber Congenital Amaurosis (LCA), a severe inherited retinal dystrophy. Opus Genetics has unveiled promising preliminary findings from their ongoing Phase 1/2 trial of OPGx-LCA5, a novel gene therapy targeting patients with LCA caused by mutations in the LCA5 gene. The data presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting highlights the persistence of subjective and signs of efficacy over one year in the first three adult patients enrolled in this trial. Trial Design and The Phase 1/2 trial of OPGx-LCA5 aims to assess both the safety and effic...
December 19, 2024
Exploring the Journey of APX3330 in Diabetic Retinopathy: A New Horizon in Ophthalmic Treatment Diabetic retinopathy is a prevalent microvascular complication of diabetes, often leading to vision impairment or loss. Treatment options have remained limited, necessitating continuous exploration into novel therapies. Opus Genetics achieves a significant milestone with FDA s Special Protocol Assessment (SPA) agreement for its Phase 3 clinical trial of APX3330, a promising therapeutic agent. This article discusses the implications of this development, focusing on trial design, primary endpoint agreements, and potential impacts on diabetic retinopathy treatment paradigms.Diabetic retinopathy, a leading cause of ...
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in the development and aseptic manufacturing of sterile injectable pharmaceuticals.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Sources:
Opus Genetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Opus Genetics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
